Evaluation of the diagnostic efficiency of systemic immune-inflammation index in prostate biopsy

Year 2021, Volume: 4 Issue: 6, 897 - 900, 24.09.2021

Mehmet Demir , İsmail Yağmur , Eyyup Sabri Pelit , Bülent Katı , İbrahim Halil Albayrak , Halil Çiftçi

https://doi.org/10.32322/jhsm.981394

Abstract

Aim: This study aimed to evaluate the diagnostic efficacy of systemic immune-inflammation index (SII) in patients with prostate cancer (PCa) who have undergone prostate biopsy and have a prostate-specific antigen (PSA) value of 4–10 ng/ml.
Material and Method: In this study we included patients with a PSA value of 4–10 ng/mL, who underwent transrectal ultrasound-guided 12-core prostate biopsy between January 2010 and March 2021. The patients were divided into two groups as those with and without cancer. Those with cancer were divided into two groups as low grade (grade 1 and 2) and high grade (grade 3–5) according to the International Society of Urologic Pathologists (ISUP) grades. PSA, neutrophil-lymphocyte ratio (NLR), prostate volume, platelet-to-lymphocyte ratio (PLR) and SII were compared between the groups.
Results: The mean age of the 182 patients included in the study was 63.4±8.0 years, and the mean PSA value was 6.69±2.45 ng/mL. Benign prostate disease were detected in 142 (78%) of the patients and PCa in 40 (22%) patients. PSA, PLR, NLR and SII did not differ in those with cancer. Low ISUP grade cancer was detected in 80% of the patients and high ISUP grade cancer in 20%. PSA and PLR values were significantly higher in patients with high ISUP grade PCa compared to those with low ISUP grade (p < 0.05). There was no difference in SII values between the two groups. PSA, PLR and SII values of patients with high ISUP grade PCa were significantly higher than those without cancer (p<0.05).
Conclusions: SII and PLR, which can be easily calculated from peripheral blood, can be an effective predictor of pre-biopsy high-grade ISUP PCa.

Keywords

prostate cancer, diagnosis, systemic immune-inflammation index, platelet-to-lymphocyteratio, biopsy

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.
• Canby-Hagino E, Hernandez J, Brand TC, Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007; 51: 27-33.
• Vickers AJ, Sjoberg DD, Ulmert D, et al. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 2014; 12: 26.
• Finne P, Fallah M, Hakama M, et al. Lead-time in the European Randomised Study of screening for prostate cancer. EurJ Cancer 2010; 46: 3102-8.
• Catalona WJ, Southwick PC, Slawin KM, et al. Prospective evaluation of percent free PSA, PSA density and age specific PSA cut-offs for prostate cancer detection and staging. Urology 2000; 56: 255-60.
• Bausch D, Pausch T, Krauss T, et al. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switchin pancreatic ductal adenocarcinoma. Angiogenesis 2011; 14: 235-43.
• Yuksel OH, Urkmez A, Akan S, Yidirim C, Verit A. Predictive value of the platelet to lymphocyte ratio in the diagnosis of prostate cancer. Asian Pac J Cancer Prev 2015; 16: 6407-12.
• Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int 2020; 20: 499.
• Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013; 31: CD004720.
• Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specificantigen test: a review of current evidence. JAMA 2014; 311: 1143-9.
• Booth N, Rissanen P, Tammela TL, Määttänen L, Taari K, Auvinen A. Health-related quality of life in the Finnish trial of screening for prostate cancer. Eur Urol 2014; 65: 39-47.
• Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol 2015; 25: 232-7.
• Bellardita L, Villa S, Valdagni R. Living with untreated prostate cancer: predictors of quality of life. Curr Opin Urol 2014; 24: 311-7.
• Ostan R, Lanzarini C, Pini E, et al. Inflammaging and cancer: a challenge for the Mediterranean diet. Nutrients 2015; 7: 2589-621.
• Li F, Hu H, Gu S, Chen X, Sun Q. Platelet to lymphocyte ratio plays an important role in prostate cancer's diagnosis and prognosis. Int J Clin Exp Med 2015; 8: 11746-51.
• Palacka P, Mego M, Mikulova T, et al. Systemic immune-inflammation index to predict survival in Caucasian patients with metastatic urothelial carcinoma. J Clin Oncol 2017; 35: e16015.
• Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-infammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg 2019; 270: 139-46.
• Wang Q, Zhu SR, Huang XP, Liu XQ, Liu JB, Tian G. Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. Eur Rev Med Pharmacol Sci 2021; 25: 1302-10.
• Gorgel SN, Akin Y, Koc EM, Kose O, Ozcan S, Yilmaz Y. Retrospective study of systemic immune-inflammation index in muscle invasive bladder cancer: initial results of single centre. Int Urol Nephrol 2020; 52: 469-73.
• Mori K, Resch I, Miura N, et al. Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. Cancer Immunol Immunother 2021; 70: 2641-50.
• Stangl-Kremser J, Mari A, Suarez-Ibarrola R, et al. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. Urol Oncol 2020; 38: 600.
• Rajwa P, Schuettfort VM, Quhal F, et al. Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. World J Urol 2021; 17.
• Murray NP, Fuentealba C, Salazar A, Reyes E. Platelet-to-lymphocyte ratio and systemic immune-inflammation index versus circulating prostate cells to predict significant prostate cancer at first biopsy. Turk J Urol 2020; 46: 115-22.
• Sonmez G, Demirtas T, Tombul ST, Akgun H, Demirtas A. Diagnostic efficiency of systemic immune-inflammation index in fusion prostate biopsy. Actas Urol Esp 2021; 45: 359-65.
• Riedl J, Kaider A, Marosi C, et al. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. Thromb Haemost 2017; 117: 90-8.
• Adhyatma KP, Warli SM. Diagnostic value of platelet-to-lymphocyte ratio in prostate cancer. Open Access Maced J Med Sci 2019; 7: 1093-6.
• Shimodaira K, Nakashima J, Nakagami Y, et al. Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy. Urol J 2020; 17: 42-9.